Carotid artery stenting: acute and long-term results

The objective of this study was to evaluate the safety and efficacy of carotid artery stenting (CAS) in high-risk patients. Carotid endarterectomy (CEA) has been shown to be more effective than medical therapy but has limitations. CAS may be a reasonable alternative, particularly in high-risk patients. The authors evaluated prospectively the safety and efficacy of CAS in 299 consecutive patients who underwent CAS of 343 extracranial carotid arteries. Of the patients enrolled, 210 (70%) would have been excluded from the major trials of CEA, and 84 (28%) were referred by vascular surgeons. This series represents a very high-risk group that included patients with unstable angina, previous ipsilateral CEA, contralateral carotid occlusion, and other severe comorbid illnesses. Seventy-four (25%) patients were aged 80 years or more. All patients had independent neurologic examination before and after the procedure. Three hundred seventy-six stents were deployed in 343 arteries. Procedural success was 99%. Mean stenosis was 75 +/- 12% before and 7 +/- 8% after the procedure. Ninety-two patients had coronary intervention. Only 56 (19%) patients were North American Symptomatic Carotid Endarterectomy Trial (NASCET) eligible. During the initial hospitalization and 30 days post-CAS, there were two (0.6%) major and seven (2.3%) minor strokes. There were no myocardial infarctions or deaths during or within 30 days of CAS. None of the NASCET-eligible patients had a stroke. At a mean follow-up period of 26 +/- 13 months, eight (2.7%) patients had asymptomatic restenosis. No additional major strokes or neurologic deaths occurred. In conclusion, CAS is feasible, can be performed even in high-risk patients, and is associated with a low restenosis rate.     

Carotid stenting

From my point of view, carotid artery stenting, in 2005, is clearly here to stay. "Houston, the Eagle has landed." The rest is up to you and me as we encourage our surgical colleagues and our various medical Societies to embrace this safe, effective, and durable technology and make it available to the patients who will really benefit from it.     

Carotid stenting.

Coding personnel should be aware of the new CPT guidelines for reporting carotid and vertebral stent placement. Payors' billing requirements for these procedures vary, and it is important to determine before billing whether the payor will accept the applicable CPT category I or III code or whether an unlisted code must be reported. Coding guidancefor these procedures will likely continue to evolve in thenear future.     

Carotid artery stenting

From the earliest experiences with carotid artery stenting (CAS) presumptive high risk features have included thrombus‐containing lesions, heavily calcified lesions, very tortuous vessels, and near occlusions. In addition patients have been routinely excluded from CAS trials if they have contra‐indications to dual antiplatelet therapy (aspirin and thienopyridines), a history of bleeding complications and severe peripheral arterial disease (PAD) making femoral artery vascular access difficult. Variables that increase the risk of CAS complications can be attributed to patient characteristics, anatomic or lesion features, and procedural factors. Clinical features such as older age (≥80 years), decreased cerebral reserve (dementia, multiple prior strokes, or intracranial microangiopathy) and angiographic characteristics such as excessive tortuosity (more than two 90° bends within 5 cm of the target lesion) and heavy calcification (concentric calcification ≥ 3 mm in width) have been associated with increased CAS complications. Other high risk CAS features include those that prolong catheter or guide wire manipulation in the aortic arch, make crossing a carotid stenosis more difficult, decrease the likelihood of successful deployment or retrieval of an embolic protection device (EPD), or make stent delivery or placement more difficult. Procedure volume for the operator and the catheterization laboratory team are critical elements in reducing the risk of the procedure. In this article, we help CAS operators better understand procedure risk to allow more intelligent case selection, further improving the outcomes of this emerging procedure.© 2013 Wiley Periodicals, Inc.     

Carotid artery stenting in asymptomatic and surgically high-risk patients: single-centre, single-operator results

BACKGROUND:

Stroke represents the third leading cause of death in developed countries and the leading cause of disability in the elderly. Because asymptomatic, surgically high-risk patients have been systematically excluded from randomized trials of carotid endarterectomy and medical therapy, the management of this group of patients is still controversial. A single-centre, single-operator registry was analyzed to evaluate feasibility and safety of carotid artery stenting (CAS) with distal protection devices in consecutive, asymptomatic, surgically high-risk patients who were scheduled for endovascular treatment of significant carotid stenoses.

METHODS:

A total of 122 consecutive, surgically high-risk, asymptomatic patients (150 carotid arteries, 59% men, mean [± SD] age 69±9 years) with severe carotid stenosis and one or more high-risk features for carotid endarterectomy were scheduled for CAS. All procedures were performed in a single centre by a single operator. All patients were prospectively asked to undergo a clinical 30-day follow-up.

RESULTS:

A total of 154 stents were implanted in 150 carotid arteries. The primary success rate was 98.7%. The rates of stenosis before and after direct CAS were 81%±9% and 10%±13%, respectively. The median of fluoroscopic time of direct CAS was 6 min (range 2.5 min to 31.5 min). At 30 days, data were available in all patients. The combined 30-day mortality and stroke rate was 1.3%.

CONCLUSIONS:

Short-term outcomes of CAS in asymptomatic, surgically high-risk patients treated by a single operator suggest a low periprocedural complication rate.     

Carotid angioplasty and stenting: New horizons

Advances in technology have made it possible for lesions that affect the carotid artery, both extra-and intracranially, to be treated by endovascular means. Depending upon the type and location of the pathology, as well as the existing comorbidities in any given patient, angioplasty and stenting may be considered an alternative to traditional methods of revascularization. In fact, in some instances, endovascular therapy may be the procedure of choice. For patients whose lesions can be treated either surgically or endovascularly, future randomized trials will help define the role of each type of procedure.     

Carotid artery stenting in octogenarians: results from the ALKK Carotid Artery Stent (CAS) Registry.

AIMS: We tried to determine the influence of age on complication rates of carotid artery stenting (CAS). METHODS AND RESULTS: Two thousand seven hundred eighty CAS procedures were included in the registry. Median age of the patients was 70.8 years, with a proportion of octogenarians of 11.2% and a significant increase between 1996 (5.9%) and 2005 (13.7%; P for trend = 0.002). In octogenarians, a symptomatic stenosis was a more frequent indication for CAS (60.7% vs. 48%, P < 0.001), the CAS procedure was aborted more frequently (6.9% vs. 2.2%; P < 0.001) and the duration of intervention was longer (Median 45 vs. 40 min; P = 0.008). Increasing age was associated with a significant increase in the in-hospital death or stroke rate (P for trend: 0.001). In-hospital death or stroke rate was also higher in octogenarians compared with younger patients (5.5 vs. 3.2%; P = 0.032, OR = 1.79; 95%CI: 1.04-3.06). Logistic regression analysis showed that age analysed as a continuous variable was a strong predictor of in-hospital death or stroke (P < 0.001), whereas octogenarians had only a trend towards a higher event rate (P = 0.062). CONCLUSION: CAS in octogenarians is performed in an increasing proportion of patients. In-hospital stroke or death rates increase significantly with older age; however, there was no excess complication rate in octogenarians.     

Carotid stenting for atherothrombosis

Cerebrovascular accident (CVA) is the third leading cause of death in North America and Europe, accounting for approximately 10-12% of all deaths.w1 CVA may have several aetiologies but is generally characterised as being either thrombotic or haemorrhagic in origin. The thrombotic causes of CVA are multiple and can be divided into large vessel occlusion, small vessel occlusion, and embolisation. Large vessel occlusion from atherothrombosis of the carotid system is responsible for approximately 25% of those afflicted by a CVA. The treatment of carotid atherothrombosis is evolving and involves risk factor management and in selected patients may warrant either surgical carotid endarterectomy or percutaneous carotid stenting. This is a review of the current understanding of carotid atherothrombosis and data regarding percutaneous approaches for those with this condition.     

Carotid artery stenting without post-dilation

Introduction: The aim of this study is to report the feasibility, safety, and 1‐year restenosis rate of carotid artery stenting (CAS) without post‐dilation. Methods: Between April 2006 and November 2009, 254 consecutive patients (68.7 ± 8.5 years old, 31% symptomatic) underwent 308 CAS procedures with the intention of avoiding post‐dilation (eligibility criteria were stenosis of less than 30% after stent placement with no overt signs of calcification). Comparison and analysis of mid‐term clinical outcomes and restenosis rates of CAS with or without post‐dilation was performed retrospectively. Results: Overall, 27 patients (study group) were eligible for treatment without post‐dilation. No significant difference in adverse events was found between the study and control group. In the study group, 2 transient ischemic attacks (7.4%) occurred immediately after the procedure and no other neurological complications were reported during the 30‐day, 6‐month, and 1‐year follow‐ups (3 patients died from causes unrelated to the procedure). Two asymptomatic restenosis cases were diagnosed in the study group within the first 12‐months after the procedure compared to 16 significant restenosis cases diagnosed in the control group (7.4% vs 5.7%, NS). All of them were successfully treated with repeated intervention. Conclusion: We suggest that CAS without post‐dilation is feasible and probably safe with a low rate of cerebrovascular events and restenosis in a selected group of patients. We also suggest that CAS with postdeployment stenosis of less than 20% and without overt signs of severe calcification might be performed without post‐dilation. (J Interven Cardiol 2012;25:190–196)     

Carotid artery stenting: state of the art

Carotid artery stenting (CAS) is growing as an alternative to carotid artery endarterectomy. Nowadays, it is performed routinely in many centers worldwide. Still, it is discussed controversially although several clinical trials have shown equivalency or superiority of catheter treatment at least in high-risk patients. What is still missing is a randomized trial in non-high-risk patients. This is an overview about the completed and ongoing trials as well as the current stent and embolic protection technology.